FDA Updates OTC Monograph Framework as OMUFA Reauthorization Covers Fiscal Years 2026 to 2030

With OMUFA reauthorization now covering FY2026–2030, FDA's refreshed OTC nonprescription drug page signals that regulatory affairs teams should be actively auditing product portfolios against the reformed monograph framework established under the CARES Act, signed into law on March 27, 2020, before submission windows tighten.

The CARES Act fundamentally restructured how certain OTC drugs reach market, replacing the legacy notice-and-comment rulemaking process with an administrative order system. That shift created two distinct regulatory pathways: the drug application process and the OTC drug monograph process. For teams managing large nonprescription portfolios, spanning categories from topical antiseptics to sunscreens to cough and cold formulations, understanding which pathway governs each SKU is now a baseline compliance requirement, not an optional review.

The updated FDA resource hub consolidates several operationally relevant references: the OTC Monographs @ FDA portal (the primary access point for monograph drugs post-CARES Act), the Rx-to-NonRx Switch List covering both full and partial switches, and the Drug Application Process page detailing options for bringing new nonprescription drugs to market, including the Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ANCU) pathway. Regulatory affairs leads should note that each pathway carries distinct data requirements and review timelines.

User fee implications are equally material. Over-the-Counter Monograph User Fees (OMUFA) directly support FDA's capacity to conduct timely safety and efficacy reviews of OTC ingredients. The FY2026–2030 reauthorization cycle means fee structures, performance goals, and submission commitments are entering a new negotiated period, a development that affects budget planning for any manufacturer with active or planned monograph submissions.

Ongoing FDA reviews of topical antiseptic active ingredients and sunscreen formulations remain open dockets, with stakeholder meeting records publicly available. QA and regulatory leads with products in either category should cross-reference current administrative orders against their ingredient lists and label claims to confirm alignment with the latest agency positions.

The FY2026–2030 OMUFA commitment letter, once finalized, will set the measurable review performance goals against which FDA's monograph program execution will be assessed through the end of the decade.

Source: FDA via What's New: Drugs RSS Feed, August 11, 2026.